Oncolytics Today: It’s time for Congress to ban alternative funding programs

Alternative funding programs (AFPs) are a problem. Employer-sponsored health plans use them as a way to lower their costs, forcing patients who need specialty medications to search for funding elsewhere. But these programs are hurting the patients they are supposed to be helping.

The PAN Foundation believes that it’s time for Congress to ban these programs. In this article for Oncolytics Today, PAN’s Chief Advocacy and Engagement Officer Amy Niles breaks down how AFPs work, how they are hurting patients, and what can be done to address them.